Author:
Ali Saleema Mehboob,Adnan Yumna,Ahmad Zubair,Farooqui Hasnain Ahmed,Chawla Tabish,Ali S. M. Adnan
Funder
University Research Council, Aga Khan University
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Molecular Biology,General Medicine
Reference52 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 71:209–249
2. Kuehn BM (2020) Looking to long-term survivors for improved pancreatic cancer treatment. JAMA 324:2242–2244
3. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL et al (2018) Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406
4. Berlin JD, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR et al (2018) An intergroup randomized phase II study of bevacizumab or Ccetuximab in combination with gemcitabine and in combination with chemoradiation in patients with resected pancreatic carcinoma: a trial of the ECOG-ACRIN cancer research group (E2204). Oncology 94:39–46
5. Ioka T, Okusaka T, Ohkawa S, Boku N, Sawaki A, Fujii Y et al (2015) Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized phase III trial. Jpn J Clin Oncol 45:439–448